(Q43039862)

12 November 2017

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). (English)

1 reference

12 November 2017

peginterferon alfa-2a

1 reference

4

Stefan Zeuzem

1 reference

12 November 2017

3

K Rajender Reddy

1 reference

12 November 2017

8

Dieter Häussinger

1 reference

12 November 2017

Samuel S Lee

1

1 reference

12 November 2017

E Jenny Heathcote

2

1 reference

12 November 2017

Michael W Fried

5

1 reference

12 November 2017

Teresa L Wright

6

1 reference

12 November 2017

Paul J Pockros

7

1 reference

12 November 2017

Coleman I Smith

9

1 reference

12 November 2017

Amy Lin

10

1 reference

12 November 2017

Stephen C Pappas

11

1 reference

12 November 2017

1 October 2002

1 reference

12 November 2017

Journal of Hepatology

1 reference

12 November 2017

37

1 reference

12 November 2017

500-506

1 reference

12 November 2017

4

1 reference

Early predictors of response to treatment in patients with chronic hepatitis C.

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Predictors of a favorable response to alpha interferon therapy for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Host and viral features in chronic HCV infection: relevance to interferon responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Performance characteristics of the COBAS AMPLICOR hepatitis C virus MONITOR Test, version 2.0.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Statistical models for predicting a beneficial response to interferon-alpha in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Factors predictive of response to interferon therapy in children with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

[Validation of the Düsseldorfer screening tool: a trait-based approach to assess psychological distress of cancer patients]

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900211-8

7 January 2021

10.1016/S0168-8278(02)00211-8

Identifiers

DOI

1 reference

12 November 2017

1 reference